-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
This article is original by Translational Medicine Network.
Please indicate the source for reprinting.
Author: John Guide: Recently, the results of the interim analysis of AstraZeneca Olapali Phase III PROpel trial have been released, showing high rates in first-line treatment of patients with metastatic castration-resistant prostate cancer The level is positive
.
As the first PARP inhibitor approved for marketing in China, it has been approved for 3 indications so far while being included in the National Medical Insurance Catalog
.
Lynparza (olaparib, olaparib) is a "first-in-class" PARP inhibitor jointly developed by AstraZeneca and Merck
.
It targets the DNA damage repair response (DDR) pathway and uses the "synthetic lethal" principle to kill cancer cells without affecting healthy cells
.
As the world's first PARP inhibitor, it has been approved for the treatment of 4 types of cancer, including ovarian cancer, breast cancer, pancreatic cancer, and prostate cancer
.
In May 2020, the drug was approved by the FDA for the treatment of homologous recombination repair (HRR) gene mutations in metastatic castration-resistant prostate cancer (mCRPC), and it is also the second PARP inhibitor approved for this indication
.
Prostate cancer is the second most common cancer among men.
Although the treatment options for patients with metastatic castration-resistant prostate cancer have increased in recent years, the 5-year survival rate is still low
.
PROpel is a randomized, double-blind, multicenter, placebo-controlled phase III clinical trial (treated with the hormone abiraterone alone) for the first-line treatment of mCRPC male patients who have not received previous chemotherapy or new hormone drugs (NHAs), and Whether or not patients carry homologous recombination repair (HRR) gene mutations, to evaluate its effectiveness, safety and tolerability
.
The interim analysis of the Phase III PROpel trial showed that compared with the hormone drug abiraterone (abiraterone), the combination of Lynparza and abiraterone in previously untreated mCRPC patients has the primary endpoint of imaging progression-free survival (rPFS) It showed statistically significant and clinically significant improvements
.
In addition, there is a trend of improvement in the overall survival (OS) of the key secondary endpoint, but the OS data is not yet mature at the time of the interim analysis
.
At the same time, the safety and tolerability are consistent with the known characteristics of each drug
.
It is worth mentioning that Lynparza is the first PARP inhibitor to show clinical benefit in the first-line treatment of prostate cancer
.
The high level of positive results from the PROpel test is expected to open up a broader market for Lynparza
.
Although the data is not yet mature, AstraZeneca and Merck have planned to submit it to regulatory agencies for review
.
At the same time, Lynparza, as the first PARP inhibitor approved for marketing in China, has been approved for 3 indications so far
.
As of June 2021, it was approved in China for the treatment of BRCA-mutated advanced prostate cancer (mCRPC)
.
Previously, in November 2019, Lynparza was included in the National Medical Insurance Directory
.
At present, Lynparza is in a leading position in the field of PARP inhibitors, with sales of US$1.
13 billion in the first half of 2021, a year-on-year increase of 15%
.
With the success of the latest first-line treatment of mCRPC and the recent positive data of adjuvant treatment of high-risk early breast cancer, Lynparza is expected to further grow strongly in the future
.
Popular·Article Gene Sequencing [Hot Discussion] How to achieve more uniform and accurate genetic testing? Shock! Two top genetic testing companies performed liquid biopsies on the same group of cancer patients, and the results were quite different.
The new coronavirus [Nature Hot Discussion] The new coronavirus is getting more and more powerful, but the protective efficacy of the vaccine is gradually weakening.
What should we do? New Coronavirus [Nature Hot Discussion] The epidemic in Fujian has spread to four places! Israel’s 1.
1 million large-scale study: The vaccinated booster shot is 19.
5 times less likely to be infected with the new crown than people who have only received two injections.
[Science] Nearly 500 million people live in areas where the coronavirus may overflow.
The new crown is just the tip of the iceberg.
There will be more SARS-like viruses! Gut microbes [Genome Medicine] is the first to use gut microbial data for the prognosis study of rheumatoid arthritis, which is expected to become the key to future treatment! Organoid Research [Nature Sub-Journal] The use of synthetic new gels can easily cultivate pancreatic "organoids" and accurately replicate human pancreatic tumor research [The Lancet] Low-dose CT screening for lung cancer can really effectively reduce mortality NS? British scientists will show you the answer through experiments! New crown virus [heavy weight] How protective is the new crown vaccine against delta virus? The US Centers for Disease Control and Prevention has given the answer: The death rate of the unvaccinated population is 11 times that of the vaccinated population! Gene Sequencing [Nature Sub-Journal] The largest DNAm gene study to date: the study of genetic mutations related to DNAm at 420,509 DNAm loci in the blood has been identified.
[Heavyweight] Johns Hopkins University scientists have discovered genetic The self-correction function can resist blood cancer, which is expected to be a major breakthrough in the treatment of blood cancer! Genetic testing [Nature Sub-Journal] The 1.
5 million largest genome-wide association study has identified nearly 600 gene loci related to anti-social behavior, alcoholism, and opioid addiction.
The new coronavirus [Nature] is a heavyweight! Why can the delta mutant virus spread so quickly and fiercely? Scientists from the University of Cambridge will take you through its recommendations and activities The 3rd Shanghai International Cancer Conference The 5th Symposium on Modern Clinical Molecular Diagnosis
Please indicate the source for reprinting.
Author: John Guide: Recently, the results of the interim analysis of AstraZeneca Olapali Phase III PROpel trial have been released, showing high rates in first-line treatment of patients with metastatic castration-resistant prostate cancer The level is positive
.
As the first PARP inhibitor approved for marketing in China, it has been approved for 3 indications so far while being included in the National Medical Insurance Catalog
.
Lynparza (olaparib, olaparib) is a "first-in-class" PARP inhibitor jointly developed by AstraZeneca and Merck
.
It targets the DNA damage repair response (DDR) pathway and uses the "synthetic lethal" principle to kill cancer cells without affecting healthy cells
.
As the world's first PARP inhibitor, it has been approved for the treatment of 4 types of cancer, including ovarian cancer, breast cancer, pancreatic cancer, and prostate cancer
.
In May 2020, the drug was approved by the FDA for the treatment of homologous recombination repair (HRR) gene mutations in metastatic castration-resistant prostate cancer (mCRPC), and it is also the second PARP inhibitor approved for this indication
.
Prostate cancer is the second most common cancer among men.
Although the treatment options for patients with metastatic castration-resistant prostate cancer have increased in recent years, the 5-year survival rate is still low
.
PROpel is a randomized, double-blind, multicenter, placebo-controlled phase III clinical trial (treated with the hormone abiraterone alone) for the first-line treatment of mCRPC male patients who have not received previous chemotherapy or new hormone drugs (NHAs), and Whether or not patients carry homologous recombination repair (HRR) gene mutations, to evaluate its effectiveness, safety and tolerability
.
The interim analysis of the Phase III PROpel trial showed that compared with the hormone drug abiraterone (abiraterone), the combination of Lynparza and abiraterone in previously untreated mCRPC patients has the primary endpoint of imaging progression-free survival (rPFS) It showed statistically significant and clinically significant improvements
.
In addition, there is a trend of improvement in the overall survival (OS) of the key secondary endpoint, but the OS data is not yet mature at the time of the interim analysis
.
At the same time, the safety and tolerability are consistent with the known characteristics of each drug
.
It is worth mentioning that Lynparza is the first PARP inhibitor to show clinical benefit in the first-line treatment of prostate cancer
.
The high level of positive results from the PROpel test is expected to open up a broader market for Lynparza
.
Although the data is not yet mature, AstraZeneca and Merck have planned to submit it to regulatory agencies for review
.
At the same time, Lynparza, as the first PARP inhibitor approved for marketing in China, has been approved for 3 indications so far
.
As of June 2021, it was approved in China for the treatment of BRCA-mutated advanced prostate cancer (mCRPC)
.
Previously, in November 2019, Lynparza was included in the National Medical Insurance Directory
.
At present, Lynparza is in a leading position in the field of PARP inhibitors, with sales of US$1.
13 billion in the first half of 2021, a year-on-year increase of 15%
.
With the success of the latest first-line treatment of mCRPC and the recent positive data of adjuvant treatment of high-risk early breast cancer, Lynparza is expected to further grow strongly in the future
.
Popular·Article Gene Sequencing [Hot Discussion] How to achieve more uniform and accurate genetic testing? Shock! Two top genetic testing companies performed liquid biopsies on the same group of cancer patients, and the results were quite different.
The new coronavirus [Nature Hot Discussion] The new coronavirus is getting more and more powerful, but the protective efficacy of the vaccine is gradually weakening.
What should we do? New Coronavirus [Nature Hot Discussion] The epidemic in Fujian has spread to four places! Israel’s 1.
1 million large-scale study: The vaccinated booster shot is 19.
5 times less likely to be infected with the new crown than people who have only received two injections.
[Science] Nearly 500 million people live in areas where the coronavirus may overflow.
The new crown is just the tip of the iceberg.
There will be more SARS-like viruses! Gut microbes [Genome Medicine] is the first to use gut microbial data for the prognosis study of rheumatoid arthritis, which is expected to become the key to future treatment! Organoid Research [Nature Sub-Journal] The use of synthetic new gels can easily cultivate pancreatic "organoids" and accurately replicate human pancreatic tumor research [The Lancet] Low-dose CT screening for lung cancer can really effectively reduce mortality NS? British scientists will show you the answer through experiments! New crown virus [heavy weight] How protective is the new crown vaccine against delta virus? The US Centers for Disease Control and Prevention has given the answer: The death rate of the unvaccinated population is 11 times that of the vaccinated population! Gene Sequencing [Nature Sub-Journal] The largest DNAm gene study to date: the study of genetic mutations related to DNAm at 420,509 DNAm loci in the blood has been identified.
[Heavyweight] Johns Hopkins University scientists have discovered genetic The self-correction function can resist blood cancer, which is expected to be a major breakthrough in the treatment of blood cancer! Genetic testing [Nature Sub-Journal] The 1.
5 million largest genome-wide association study has identified nearly 600 gene loci related to anti-social behavior, alcoholism, and opioid addiction.
The new coronavirus [Nature] is a heavyweight! Why can the delta mutant virus spread so quickly and fiercely? Scientists from the University of Cambridge will take you through its recommendations and activities The 3rd Shanghai International Cancer Conference The 5th Symposium on Modern Clinical Molecular Diagnosis
